相关实验视频

Updated: May 6, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

用Dostarlimab治疗子宫内膜癌后的双边松膜炎:一个病例报告

Jacobo Emilio Enríquez-Fuentes¹, Jaime Lorenzo-Castro¹, Marco Antonio Pascual-Santiago¹

¹Department of Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain.

Ocular immunology and inflammation

|September 16, 2024

概括

这份病例报告详细介绍了一名患者,在治疗子宫内膜癌的多斯塔利马布治疗后,该患者患上了双侧膜炎. 及时的皮质类固醇治疗导致症状改善,眼内炎症得到缓解.

科学领域:

眼科医生眼科眼科
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

像Dostarlimab这样的免疫检查点抑制剂 (ICI) 在癌症治疗中至关重要.
虽然有效,但ICI可能会导致与免疫相关的不良事件.
之前没有记录过多斯塔利马布的眼部副作用.

研究的目的:

报告一种罕见的双边松风炎病例.
为了调查Dostarlimab治疗的潜在不良反应.

主要方法:

本研究提出了一个案例报告.
分析了用Dostarlimab治疗的子宫内膜癌患者的临床表现和治疗.

主要成果:

一名73岁的妇女患有双侧膜炎,视力敏度下降,前腔炎和视炎.
该患者有免疫介导的甲状腺问题史,随后患上肺炎和胰腺炎.
用皮质类固醇治疗导致症状改善和眼内炎症的消失.

结论:

作为一种免疫检查点抑制剂的多斯塔利马布可能会诱导双边松膜炎.
这一案例凸显了多斯塔利马布治疗对眼睛的潜在毒性.
需要进一步的研究来了解与Dostarlimab相关的不良事件的全部范围.

关键词:

双边松膜炎的发生我们的朋友们很友好.用生物处理处理.癌症治疗治疗治疗癌症这是子宫内膜癌的癌症.

更多相关视频

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...